Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues

Current Medicinal Chemistry

Volumn 18, Issue 26, 2011, Pages 4053-4064

  Orsucci, D ^a   Mancuso, M ^a   Ienco, E Caldarazzo ^a   LoGerfo, A ^a   Siciliano, G ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

CoQ10; Electron transport chain; Idebenone; MtDNA; Neurodegenerative disease; Oxidative stress; ROS; Ubiquinone

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; CARNITINE; IDEBENONE; MINOCYCLINE; MITOCHONDRIAL DNA; MITOQUINONE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REMACEMIDE; RESVERATROL; RETINOL; THIOCTIC ACID; UBIDECARENONE; UNCLASSIFIED DRUG;

ALPHA TOCOPHEROL DEFICIENCY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; COENZYME Q10 DEFICIENCY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FRIEDREICH ATAXIA; GENETIC TRANSDUCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HUNTINGTON CHOREA; LUNG DISEASE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUPPLEMENTATION; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL; VITAMIN DEFICIENCY;

ANIMALS; HUMANS; MICRONUTRIENTS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; UBIQUINONE;

EID: 80052211991     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796957257     Document Type: Review

References (128)

1. DiMauro, S.; Schon, E.A., Mitochondrial respiratory-chain diseases. N Engl J Med, 2003, 348(26), 2656-2668. (Pubitemid 36741594)
2. Chan, D.C., Mitochondria: dynamic organelles in disease, aging, and development. Cell, 2006, 125(7), 1241-1252. (Pubitemid 43929096)
3. Shokolenko, I.; Venediktova, N.; Bochkareva, A.; Wilson, G.L.; Alexeyev, M.F., Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res, 2009, 37(8), 2539-2548.
4. Turrens, J.F., Mitochondrial formation of reactive oxygen species. J Physiol, 2003, 552(Pt 2), 335-344. (Pubitemid 37321833)
5. Dallner, G.; Sindelar, P.J., Regulation of ubiquinone metabolism. Free Radic Biol Med, 2000, 29(3-4), 285-294.
6. Gutierrez-Mariscal, F.M.; Perez-Martinez, P.; Delgado-Lista, J.; Yubero-Serrano, E.M.; Camargo, A.; Delgado-Casado, N.; Cruz-Teno, C.; Santos-Gonzalez, M.; Rodriguez-Cantalejo, F.; Castano, J.P.; Villalba-Montoro, J.M.; Fuentes, F.; Perez-Jimenez, F.; Lopez-Miranda, J., Mediterranean diet supplemented with coenzyme Q10 induces postprandial changes in p53 in response to oxidative DNA damage in elderly subjects. Age (Dordr), 2011.
7. Bour, S.; Carmona, M.C.; Galinier, A.; Caspar-Bauguil, S.; Van Gaal, L.; Staels, B.; Penicaud, L.; Casteilla, L., Coenzyme Q as an antiadipogenic factor. Antioxid Redox Signal, 2011, 14(3), 403-413.
8. Dai, Y.L.; Luk, T.H.; Yiu, K.H.; Wang, M.; Yip, P.M.; Lee, S.W.; Li, S.W.; Tam, S.; Fong, B.; Lau, C.P.; Siu, C.W.; Tse, H.F., Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: A randomized controlled trial. Atherosclerosis, 2011, 216(2), 395-401.
9. El-Abhar, H.S., Coenzyme Q10: a novel gastroprotective effect via modulation of vascular permeability, prostaglandin E, nitric oxide and redox status in indomethacin-induced gastric ulcer model. Eur J Pharmacol, 2010, 649(1-3), 314-319.
10. Marcoff, L.; Thompson, P.D., The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol, 2007, 49(23), 2231-2237. (Pubitemid 46856819)
11. Mizuno, K.; Tanaka, M.; Nozaki, S.; Mizuma, H.; Ataka, S.; Tahara, T.; Sugino, T.; Shirai, T.; Kajimoto, Y.; Kuratsune, H.; Kajimoto, O.; Watanabe, Y., Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition, 2008, 24(4), 293-299.
12. Mancuso, M.; Orsucci, D.; Volpi, L.; Calsolaro, V.; Siciliano, G., Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets, 2010, 11(1), 111-121.
13. Di Prospero, N.A.; Sumner, C.J.; Penzak, S.R.; Ravina, B.; Fischbeck, K.H.; Taylor, J.P., Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol, 2007, 64(6), 803-808. (Pubitemid 46919834)
14. Bodmer, M.; Vankan, P.; Dreier, M.; Kutz, K.W.; Drewe, J., Pharmacokinetics and metabolism of idebenone in healthy male subjects. Eur J Clin Pharmacol, 2009, 65(5), 493-501.
15. Esposti, M.D.; Ngo, A.; Ghelli, A.; Benelli, B.; Carelli, V.; McLennan, H.; Linnane, A.W., The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys, 1996, 330(2), 395-400. (Pubitemid 26172376)
16. Miles, M.V., The uptake and distribution of coenzyme Q10. Mitochondrion, 2007, 7 Suppl, S72-77.
17. Bhagavan, H.N.; Chopra, R.K., Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res, 2006, 40(5), 445-453.
18. Bonakdar, R.A.; Guarneri, E., Coenzyme Q10. Am Fam Physician, 2005, 72(6), 1065-1070. (Pubitemid 43093261)
19. Land, J.M.; Heales, S.J.; Duncan, A.J.; Hargreaves, I.P., Some observations upon biochemical causes of ataxia and a new disease entity ubiquinone, CoQ10 deficiency. Neurochem Res, 2007, 32(4-5), 837-843. (Pubitemid 46481312)
20. Beg, S.; Javed, S.; Kohli, K., Bioavailability enhancement of coenzyme Q10: an extensive review of patents. Recent Pat Drug Deliv Formul, 2010, 4(3), 245-255.
21. Fetoni, A.R.; Piacentini, R.; Fiorita, A.; Paludetti, G.; Troiani, D., Watersoluble Coenzyme Q10 formulation (Q-ter) promotes outer hair cell survival in a guinea pig model of noise induced hearing loss (NIHL). Brain Res, 2009, 1257, 108-116.
22. Cocheme, H.M.; Kelso, G.F.; James, A.M.; Ross, M.F.; Trnka, J.; Mahendiran, T.; Asin-Cayuela, J.; Blaikie, F.H.; Manas, A.R.; Porteous, C.M.; Adlam, V.J.; Smith, R.A.; Murphy, M.P., Mitochondrial targeting of quinones: therapeutic implications. Mitochondrion, 2007, 7 Suppl, S94-102. (Pubitemid 46722288)
23. James, A.M.; Cocheme, H.M.; Smith, R.A.; Murphy, M.P., Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem, 2005, 280(22), 21295-21312. (Pubitemid 40805692)
24. Rodriguez-Cuenca, S.; Cocheme, H.M.; Logan, A.; Abakumova, I.; Prime, T.A.; Rose, C.; Vidal-Puig, A.; Smith, A.C.; Rubinsztein, D.C.; Fearnley, I.M.; Jones, B.A.; Pope, S.; Heales, S.J.; Lam, B.Y.; Neogi, S.G.; McFarlane, I.; James, A.M.; Smith, R.A.; Murphy, M.P., Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic Biol Med, 2010, 48(1), 161-172.
25. Schaefer, A.M.; McFarland, R.; Blakely, E.L.; He, L.; Whittaker, R.G.; Taylor, R.W.; Chinnery, P.F.; Turnbull, D.M., Prevalence of mitochondrial DNA disease in adults. Ann Neurol, 2008, 63(1), 35-39. (Pubitemid 351240549)
26. Mancuso, M.; Orsucci, D.; Coppede, F.; Nesti, C.; Choub, A.; Siciliano, G., Diagnostic approach to mitochondrial disorders: the need for a reliable biomarker. Curr Mol Med, 2009, 9(9), 1095-1107.
27. Lopez-Gallardo, E.; Lopez-Perez, M.J.; Montoya, J.; Ruiz-Pesini, E., CPEO and KSS differ in the percentage and location of the mtDNA deletion. Mitochondrion, 2009, 9(5), 314-317.
28. Mancuso, M.; Coppede, F.; Migliore, L.; Siciliano, G.; Murri, L., Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimers Dis, 2006, 10(1), 59-73. (Pubitemid 44401367)
29. Di Lisa, F.; Kaludercic, N.; Carpi, A.; Menabo, R.; Giorgio, M., Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66(Shc) and monoamine oxidase. Basic Res Cardiol, 2009, 104(2), 131-139.
30. Somayajulu, M.; McCarthy, S.; Hung, M.; Sikorska, M.; Borowy-Borowski, H.; Pandey, S., Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10. Neurobiol Dis, 2005, 18(3), 618-627. (Pubitemid 40332719)
31. Lee, D.W.; Selamoglu, N.; Lanciano, P.; Cooley, J.W.; Forquer, I.; Kramer, D.M.; Daldal, F., Loss of a conserved tyrosine residue of cytochrome b induces reactive oxygen species production by cytochrome BC1. J Biol Chem, 2011, 286(20), 18139-48.
32. Vives-Bauza, C.; Gonzalo, R.; Manfredi, G.; Garcia-Arumi, E.; Andreu, A.L., Enhanced ROS production and antioxidant defenses in cybrids harbouring mutations in mtDNA. Neurosci Lett, 2006, 391(3), 136-141. (Pubitemid 41736187)
33. Hargreaves, I.P.; Sheena, Y.; Land, J.M.; Heales, S.J., Glutathione deficiency in patients with mitochondrial disease: implications for pathogenesis and treatment. J Inherit Metab Dis, 2005, 28(1), 81-88. (Pubitemid 40253986)
34. Atkuri, K.R.; Cowan, T.M.; Kwan, T.; Ng, A.; Herzenberg, L.A.; Enns, G.M., Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia. Proc Natl Acad Sci U S A, 2009, 106(10), 3941-3945.
35. Mancuso, M.; Orsucci, D.; Logerfo, A.; Rocchi, A.; Petrozzi, L.; Nesti, C.; Galetta, F.; Santoro, G.; Murri, L.; Siciliano, G., Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. J Neurol, 2010, 257(5), 774-781.
36. Orsucci, D.; Filosto, M.; Siciliano, G.; Mancuso, M., Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction. Nutr Rev, 2009, 67(8), 427-438.
37. Chinnery, P.; Majamaa, K.; Turnbull, D.; Thorburn, D., Treatment for mitochondrial disorders. Cochrane Database Syst Rev, 2006(1), CD004426.
38. Sacconi, S.; Trevisson, E.; Salviati, L.; Ayme, S.; Rigal, O.; Redondo, A.G.; Mancuso, M.; Siciliano, G.; Tonin, P.; Angelini, C.; Aure, K.; Lombes, A.; Desnuelle, C., Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord, 2010, 20(1), 44-48.
39. Chen, R.S.; Huang, C.C.; Chu, N.S., Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol, 1997, 37(4), 212-218.
40. Glover, E.I.; Martin, J.; Maher, A.; Thornhill, R.E.; Moran, G.R.; Tarnopolsky, M.A., A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve, 2010, 42(5), 739-748.
41. DiMauro, S.; Quinzii, C.M.; Hirano, M., Mutations in coenzyme Q10 biosynthetic genes. J Clin Invest, 2007, 117(3), 587-589. (Pubitemid 46348513)
42. Quinzii, C.M.; Lopez, L.C.; Naini, A.; DiMauro, S.; Hirano, M., Human CoQ10 deficiencies. Biofactors, 2008, 32(1-4), 113-118.
43. Gempel, K.; Topaloglu, H.; Talim, B.; Schneiderat, P.; Schoser, B.G.; Hans, V.H.; Palmafy, B.; Kale, G.; Tokatli, A.; Quinzii, C.; Hirano, M.; Naini, A.; DiMauro, S.; Prokisch, H.; Lochmuller, H.; Horvath, R., The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electrontransferring- flavoprotein dehydrogenase (ETFDH) gene. Brain, 2007, 130(Pt 8), 2037-2044. (Pubitemid 47236610)
44. Duncan, A.J.; Bitner-Glindzicz, M.; Meunier, B.; Costello, H.; Hargreaves, I.P.; Lopez, L.C.; Hirano, M.; Quinzii, C.M.; Sadowski, M.I.; Hardy, J.; Singleton, A.; Clayton, P.T.; Rahman, S., A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet, 2009, 84(5), 558-566.
45. Lagier-Tourenne, C.; Tazir, M.; Lopez, L.C.; Quinzii, C.M.; Assoum, M.; Drouot, N.; Busso, C.; Makri, S.; Ali-Pacha, L.; Benhassine, T.; Anheim, M.; Lynch, D.R.; Thibault, C.; Plewniak, F.; Bianchetti, L.; Tranchant, C.; Poch, O.; DiMauro, S.; Mandel, J.L.; Barros, M.H.; Hirano, M.; Koenig, M., ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet, 2008, 82(3), 661-672. (Pubitemid 351735958)
46. Mollet, J.; Delahodde, A.; Serre, V.; Chretien, D.; Schlemmer, D.; Lombes, A.; Boddaert, N.; Desguerre, I.; de Lonlay, P.; de Baulny, H.O.; Munnich, A.; Rotig, A., CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am J Hum Genet, 2008, 82(3), 623-630. (Pubitemid 351735957)
47. Le Ber, I.; Dubourg, O.; Benoist, J.F.; Jardel, C.; Mochel, F.; Koenig, M.; Brice, A.; Lombes, A.; Durr, A., Muscle coenzyme Q10 deficiencies in ataxia with oculomotor apraxia 1. Neurology, 2007, 68(4), 295-297. (Pubitemid 46148344)
48. Castellotti, B.; Mariotti, C.; Rimoldi, M.; Fancellu, R.; Plumari, M.; Caimi, S.; Uziel, G.; Nardocci, N.; Moroni, I.; Zorzi, G.; Pareyson, D.; Di Bella, D.; Di Donato, S.; Taroni, F.; Gellera, C., Ataxia with oculomotor apraxia type1 (AOA1): novel and recurrent aprataxin mutations, coenzyme Q10 analyses, and clinical findings in Italian patients. Neurogenetics, 2011.
49. Quinzii, C.M.; Lopez, L.C.; Gilkerson, R.W.; Dorado, B.; Coku, J.; Naini, A.B.; Lagier-Tourenne, C.; Schuelke, M.; Salviati, L.; Carrozzo, R.; Santorelli, F.; Rahman, S.; Tazir, M.; Koenig, M.; DiMauro, S.; Hirano, M., Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. FASEB J, 2010, 24(10), 3733-3743.
50. Lopez, L.C.; Quinzii, C.M.; Area, E.; Naini, A.; Rahman, S.; Schuelke, M.; Salviati, L.; Dimauro, S.; Hirano, M., Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time-and compound-dependent effects. PLoS One, 2010, 5(7), e11897.
51. Campuzano, V.; Montermini, L.; Molto, M.D.; Pianese, L.; Cossee, M.; Cavalcanti, F.; Monros, E.; Rodius, F.; Duclos, F.; Monticelli, A.; Zara, F.; Canizares, J.; Koutnikova, H.; Bidichandani, S.I.; Gellera, C.; Brice, A.; Trouillas, P.; De Michele, G.; Filla, A.; De Frutos, R.; Palau, F.; Patel, P.I.; Di Donato, S.; Mandel, J.L.; Cocozza, S.; Koenig, M.; Pandolfo, M., Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science, 1996, 271(5254), 1423-1427. (Pubitemid 26089479)
52. Fogel, B.L.; Perlman, S., Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol, 2007, 6(3), 245-257. (Pubitemid 46228080)
53. Kipps, A.; Alexander, M.; Colan, S.D.; Gauvreau, K.; Smoot, L.; Crawford, L.; Darras, B.T.; Blume, E.D., The longitudinal course of cardiomyopathy in Friedreich's ataxia during childhood. Pediatr Cardiol, 2009, 30(3), 306-310.
54. Pandolfo, M., Friedreich ataxia. Arch Neurol, 2008, 65(10), 1296-1303.
55. La Pean, A.; Jeffries, N.; Grow, C.; Ravina, B.; Di Prospero, N.A., Predictors of progression in patients with Friedreich ataxia. Mov Disord, 2008, 23(14), 2026-2032.
56. Campuzano, V.; Montermini, L.; Lutz, Y.; Cova, L.; Hindelang, C.; Jiralerspong, S.; Trottier, Y.; Kish, S.J.; Faucheux, B.; Trouillas, P.; Authier, F.J.; Durr, A.; Mandel, J.L.; Vescovi, A.; Pandolfo, M.; Koenig, M., Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet, 1997, 6(11), 1771-1780. (Pubitemid 27460350)
57. Levi, S.; Rovida, E., The role of iron in mitochondrial function. Biochim Biophys Acta, 2009, 1790(7), 629-636.
58. Correia, A.R.; Wang, T.; Craig, E.A.; Gomes, C.M., Iron-binding activity in yeast frataxin entails a trade off with stability in the alpha1/beta1 acidic ridge region. Biochem J, 2010, 426(2), 197-203.
59. Huang, M.L.; Becker, E.M.; Whitnall, M.; Rahmanto, Y.S.; Ponka, P.; Richardson, D.R., Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci U S A, 2009, 106(38), 16381-16386.
60. Richardson, D.R.; Huang, M.L.; Whitnall, M.; Becker, E.M.; Ponka, P.; Rahmanto, Y.S., The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia. J Mol Med, 2010, 88(4), 323-329.
61. Sparaco, M.; Gaeta, L.M.; Santorelli, F.M.; Passarelli, C.; Tozzi, G.; Bertini, E.; Simonati, A.; Scaravilli, F.; Taroni, F.; Duyckaerts, C.; Feleppa, M.; Piemonte, F., Friedreich's ataxia: oxidative stress and cytoskeletal abnormalities. J Neurol Sci, 2009, 287(1-2), 111-118.
62. Gakh, O.; Park, S.; Liu, G.; Macomber, L.; Imlay, J.A.; Ferreira, G.C.; Isaya, G., Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum Mol Genet, 2006, 15(3), 467-479. (Pubitemid 43159898)
63. Rustin, P.; von Kleist-Retzow, J.C.; Chantrel-Groussard, K.; Sidi, D.; Munnich, A.; Rotig, A., Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet, 1999, 354(9177), 477-479. (Pubitemid 29368927)
64. Lodi, R.; Cooper, J.M.; Bradley, J.L.; Manners, D.; Styles, P.; Taylor, D.J.; Schapira, A.H., Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci U S A, 1999, 96(20), 11492-11495. (Pubitemid 29487408)
65. Giacchetti, M.; Monticelli, A.; De Biase, I.; Pianese, L.; Turano, M.; Filla, A.; De Michele, G.; Cocozza, S., Mitochondrial DNA haplogroups influence the Friedreich's ataxia phenotype. J Med Genet, 2004, 41(4), 293-295. (Pubitemid 38496775)
66. Heidari, M.M.; Houshmand, M.; Hosseinkhani, S.; Nafissi, S.; Scheiber-Mojdehkar, B.; Khatami, M., Association between trinucleotide CAG repeats of the DNA polymerase gene (POLG) with age of onset of Iranian Friedreich's ataxia patients. Neurol Sci, 2008, 29(6), 489-493.
67. Kearney, M.; Orrell, R.W.; Fahey, M.; Pandolfo, M., Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev, 2009(4), CD007791.
68. Seznec, H.; Simon, D.; Bouton, C.; Reutenauer, L.; Hertzog, A.; Golik, P.; Procaccio, V.; Patel, M.; Drapier, J.C.; Koenig, M.; Puccio, H., Friedreich ataxia: the oxidative stress paradox. Hum Mol Genet, 2005, 14(4), 463-474. (Pubitemid 40277462)
69. Jauslin, M.L.; Meier, T.; Smith, R.A.; Murphy, M.P., Mitochondria- targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J, 2003, 17(13), 1972-1974.
70. Jauslin, M.L.; Wirth, T.; Meier, T.; Schoumacher, F., A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum Mol Genet, 2002, 11(24), 3055-3063. (Pubitemid 35414819)
71. Seznec, H.; Simon, D.; Monassier, L.; Criqui-Filipe, P.; Gansmuller, A.; Rustin, P.; Koenig, M.; Puccio, H., Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet, 2004, 13(10), 1017-1024. (Pubitemid 38702188)
72. Schulz, J.B.; Dehmer, T.; Schols, L.; Mende, H.; Hardt, C.; Vorgerd, M.; Burk, K.; Matson, W.; Dichgans, J.; Beal, M.F.; Bogdanov, M.B., Oxidative stress in patients with Friedreich ataxia. Neurology, 2000, 55(11), 1719-1721.
73. Cooper, J.M.; Schapira, A.H., Friedreich's ataxia: coenzyme Q10 and vitamin E therapy. Mitochondrion, 2007, 7 Suppl, S127-135. (Pubitemid 46712240)
74. Rustin, P.; Rotig, A.; Munnich, A.; Sidi, D., Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic Res, 2002, 36(4), 467-469. (Pubitemid 35154096)
75. Hausse, A.O.; Aggoun, Y.; Bonnet, D.; Sidi, D.; Munnich, A.; Rotig, A.; Rustin, P., Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart, 2002, 87(4), 346-349. (Pubitemid 34270947)
76. Mariotti, C.; Solari, A.; Torta, D.; Marano, L.; Fiorentini, C.; Di Donato, S., Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology, 2003, 60(10), 1676-1679. (Pubitemid 36618100)
77. Di Prospero, N.A.; Baker, A.; Jeffries, N.; Fischbeck, K.H., Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol, 2007, 6(10), 878-886. (Pubitemid 47404985)
78. Pineda, M.; Arpa, J.; Montero, R.; Aracil, A.; Dominguez, F.; Galvan, M.; Mas, A.; Martorell, L.; Sierra, C.; Brandi, N.; Garcia-Arumi, E.; Rissech, M.; Velasco, D.; Costa, J.A.; Artuch, R., Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol, 2008, 12(6), 470-475.
79. Drinkard, B.E.; Keyser, R.E.; Paul, S.M.; Arena, R.; Plehn, J.F.; Yanovski, J.A.; Di Prospero, N.A., Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia. Arch Phys Med Rehabil, 2010, 91(7), 1044-1050.
80. Lagedrost, S.J.; Sutton, M.S.; Cohen, M.S.; Satou, G.M.; Kaufman, B.D.; Perlman, S.L.; Rummey, C.; Meier, T.; Lynch, D.R., Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J, 2011, 161(3), 639-645 e631.
81. Lynch, D.R.; Perlman, S.L.; Meier, T., A phase 3, double-blind, placebocontrolled trial of idebenone in friedreich ataxia. Arch Neurol, 2010, 67(8), 941-947.
82. Hart, P.E.; Lodi, R.; Rajagopalan, B.; Bradley, J.L.; Crilley, J.G.; Turner, C.; Blamire, A.M.; Manners, D.; Styles, P.; Schapira, A.H.; Cooper, J.M., Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol, 2005, 62(4), 621-626. (Pubitemid 40489896)
83. Cooper, J.M.; Korlipara, L.V.; Hart, P.E.; Bradley, J.L.; Schapira, A.H., Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol, 2008, 15(12), 1371-1379.
84. Pandolfo, M., Drug Insight: antioxidant therapy in inherited ataxias. Nat Clin Pract Neurol, 2008, 4(2), 86-96. (Pubitemid 351248066)
85. Schols, L.; Zange, J.; Abele, M.; Schillings, M.; Skipka, G.; Kuntz-Hehner, S.; van Beekvelt, M.C.; Colier, W.N.; Muller, K.; Klockgether, T.; Przuntek, H.; Vorgerd, M., L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm, 2005, 112(6), 789-796. (Pubitemid 40655570)
86. Schulz, J.B.; Boesch, S.; Burk, K.; Durr, A.; Giunti, P.; Mariotti, C.; Pousset, F.; Schols, L.; Vankan, P.; Pandolfo, M., Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol, 2009, 5(4), 222-234.
87. Mancuso, M.; Orsucci, D.; Choub, A.; Siciliano, G., Current and emerging treatment options in the management of Friedreich ataxia. Neuropsychiatr Dis Treat, 2010, 6, 491-499.
88. Wadsworth, T.L.; Bishop, J.A.; Pappu, A.S.; Woltjer, R.L.; Quinn, J.F., Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J Alzheimers Dis, 2008, 14(2), 225-234. (Pubitemid 352040040)
89. Isobe, C.; Abe, T.; Terayama, Y., Increase in the oxidized/total coenzyme Q-10 ratio in the cerebrospinal fluid of Alzheimer's disease patients. Dement Geriatr Cogn Disord, 2009, 28(5), 449-454.
90. Moreira, P.I.; Santos, M.S.; Sena, C.; Nunes, E.; Seica, R.; Oliveira, C.R., CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp Neurol, 2005, 196(1), 112-119. (Pubitemid 41416653)
91. Li, G.; Jack, C.R.; Yang, X.F.; Yang, E.S., Diet supplement CoQ10 delays brain atrophy in aged transgenic mice with mutations in the amyloid precursor protein: an in vivo volume MRI study. Biofactors, 2008, 32(1-4), 169-178.
92. Yang, X.; Dai, G.; Li, G.; Yang, E.S., Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease. J Mol Neurosci, 2010, 41(1), 110-113.
93. Ishrat, T.; Khan, M.B.; Hoda, M.N.; Yousuf, S.; Ahmad, M.; Ansari, M.A.; Ahmad, A.S.; Islam, F., Coenzyme Q10 modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats. Behav Brain Res, 2006, 171(1), 9-16. (Pubitemid 43728393)
94. McDonald, S.R.; Sohal, R.S.; Forster, M.J., Concurrent administration of coenzyme Q10 and alpha-tocopherol improves learning in aged mice. Free Radic Biol Med, 2005, 38(6), 729-736. (Pubitemid 40249743)
95. Manczak, M.; Mao, P.; Calkins, M.J.; Cornea, A.; Reddy, A.P.; Murphy, M.P.; Szeto, H.H.; Park, B.; Reddy, P.H., Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis, 2010, 20 Suppl 2, S609-631.
96. Hattingen, E.; Magerkurth, J.; Pilatus, U.; Mozer, A.; Seifried, C.; Steinmetz, H.; Zanella, F.; Hilker, R., Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain, 2009, 132(Pt 12), 3285-3297.
97. Bueler, H., Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol, 2009, 218(2), 235-246.
98. Gu, M.; Cooper, J.M.; Taanman, J.W.; Schapira, A.H., Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol, 1998, 44(2), 177-186. (Pubitemid 28374105)
99. Mancuso, M.; Filosto, M.; Orsucci, D.; Siciliano, G., Mitochondrial DNA sequence variation and neurodegeneration. Hum Genomics, 2008, 3(1), 71-78.
100. Hargreaves, I.P.; Lane, A.; Sleiman, P.M., The coenzyme Q10 status of the brain regions of Parkinson's disease patients. Neurosci Lett, 2008, 447(1), 17-19.
101. Isobe, C.; Abe, T.; Terayama, Y., Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci Lett, 2010, 469(1), 159-163.
102. Winkler-Stuck, K.; Wiedemann, F.R.; Wallesch, C.W.; Kunz, W.S., Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. J Neurol Sci, 2004, 220(1-2), 41-48. (Pubitemid 38622096)
103. Kooncumchoo, P.; Sharma, S.; Porter, J.; Govitrapong, P.; Ebadi, M., Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J Mol Neurosci, 2006, 28(2), 125-141.
104. Shults, C.W.; Oakes, D.; Kieburtz, K.; Beal, M.F.; Haas, R.; Plumb, S.; Juncos, J.L.; Nutt, J.; Shoulson, I.; Carter, J.; Kompoliti, K.; Perlmutter, J.S.; Reich, S.; Stern, M.; Watts, R.L.; Kurlan, R.; Molho, E.; Harrison, M.; Lew, M., Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol, 2002, 59(10), 1541-1550.
105. Storch, A.; Jost, W.H.; Vieregge, P.; Spiegel, J.; Greulich, W.; Durner, J.; Muller, T.; Kupsch, A.; Henningsen, H.; Oertel, W.H.; Fuchs, G.; Kuhn, W.; Niklowitz, P.; Koch, R.; Herting, B.; Reichmann, H., Randomized, doubleblind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol, 2007, 64(7), 938-944. (Pubitemid 47047992)
106. Ghosh, A.; Chandran, K.; Kalivendi, S.V.; Joseph, J.; Antholine, W.E.; Hillard, C.J.; Kanthasamy, A.; Kalyanaraman, B., Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic Biol Med, 2010, 49(11), 1674-1684.
107. Snow, B.J.; Rolfe, F.L.; Lockhart, M.M.; Frampton, C.M.; O'Sullivan, J.D.; Fung, V.; Smith, R.A.; Murphy, M.P.; Taylor, K.M., A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord, 2010, 25(11), 1670-1674.
108. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology, 2007, 68(1), 20-28.
109. Stamelou, M.; Reuss, A.; Pilatus, U.; Magerkurth, J.; Niklowitz, P.; Eggert, K.M.; Krisp, A.; Menke, T.; Schade-Brittinger, C.; Oertel, W.H.; Hoglinger, G.U., Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord, 2008, 23(7), 942-949.
110. Kim, J.; Moody, J.P.; Edgerly, C.K.; Bordiuk, O.L.; Cormier, K.; Smith, K.; Beal, M.F.; Ferrante, R.J., Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet, 2010, 19(20), 3919-3935.
111. Perez-De la Cruz, V.; Carrillo-Mora, P.; Santamaria, A., Huntington's disease and mitochondrial alterations: emphasis on experimental models. J Bioenerg Biomembr, 2010, 42(3), 207-215.
112. Ciammola, A.; Sassone, J.; Sciacco, M.; Mencacci, N.E.; Ripolone, M.; Bizzi, C.; Colciago, C.; Moggio, M.; Parati, G.; Silani, V.; Malfatto, G., Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease. Mov Disord, 2011, 26(1), 130-137.
113. Kasparova, S.; Sumbalova, Z.; Bystricky, P.; Kucharska, J.; Liptaj, T.; Mlynarik, V.; Gvozdjakova, A., Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem Int, 2006, 48(2), 93-99. (Pubitemid 41832443)
114. Smith, K.M.; Matson, S.; Matson, W.R.; Cormier, K.; Del Signore, S.J.; Hagerty, S.W.; Stack, E.C.; Ryu, H.; Ferrante, R.J., Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta, 2006, 1762(6), 616-626. (Pubitemid 43903119)
115. Stack, E.C.; Smith, K.M.; Ryu, H.; Cormier, K.; Chen, M.; Hagerty, S.W.; Del Signore, S.J.; Cudkowicz, M.E.; Friedlander, R.M.; Ferrante, R.J., Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta, 2006, 1762(3), 373-380. (Pubitemid 43172854)
116. Menalled, L.B.; Patry, M.; Ragland, N.; Lowden, P.A.; Goodman, J.; Minnich, J.; Zahasky, B.; Park, L.; Leeds, J.; Howland, D.; Signer, E.; Tobin, A.J.; Brunner, D., Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One, 2010, 5(3), e9793.
117. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology, 2001, 57(3), 397-404.
118. Hyson, H.C.; Kieburtz, K.; Shoulson, I.; McDermott, M.; Ravina, B.; de Blieck, E.A.; Cudkowicz, M.E.; Ferrante, R.J.; Como, P.; Frank, S.; Zimmerman, C.; Ferrante, K.; Newhall, K.; Jennings, D.; Kelsey, T.; Walker, F.; Hunt, V.; Daigneault, S.; Goldstein, M.; Weber, J.; Watts, A.; Beal, M.F.; Browne, S.E.; Metakis, L.J., Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov Disord, 2010, 25(12), 1924-1928.
119. Crugnola, V.; Lamperti, C.; Lucchini, V.; Ronchi, D.; Peverelli, L.; Prelle, A.; Sciacco, M.; Bordoni, A.; Fassone, E.; Fortunato, F.; Corti, S.; Silani, V.; Bresolin, N.; Di Mauro, S.; Comi, G.P.; Moggio, M., Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch Neurol, 2010, 67(7), 849-854.
120. Keeney, P.M.; Bennett, J.P., Jr., ALS spinal neurons show varied and reduced mtDNA gene copy numbers and increased mtDNA gene deletions. Mol Neurodegener, 2010, 5, 21.
121. Sohmiya, M.; Tanaka, M.; Suzuki, Y.; Tanino, Y.; Okamoto, K.; Yamamoto, Y., An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J Neurol Sci, 2005, 228(1), 49-53. (Pubitemid 39656494)
122. Ferrante, K.L.; Shefner, J.; Zhang, H.; Betensky, R.; O'Brien, M.; Yu, H.; Fantasia, M.; Taft, J.; Beal, M.F.; Traynor, B.; Newhall, K.; Donofrio, P.; Caress, J.; Ashburn, C.; Freiberg, B.; O'Neill, C.; Paladenech, C.; Walker, T.; Pestronk, A.; Abrams, B.; Florence, J.; Renna, R.; Schierbecker, J.; Malkus, B.; Cudkowicz, M., Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology, 2005, 65(11), 1834-1836.
123. Kaufmann, P.; Thompson, J.L.; Levy, G.; Buchsbaum, R.; Shefner, J.; Krivickas, L.S.; Katz, J.; Rollins, Y.; Barohn, R.J.; Jackson, C.E.; Tiryaki, E.; Lomen-Hoerth, C.; Armon, C.; Tandan, R.; Rudnicki, S.A.; Rezania, K.; Sufit, R.; Pestronk, A.; Novella, S.P.; Heiman-Patterson, T.; Kasarskis, E.J.; Pioro, E.P.; Montes, J.; Arbing, R.; Vecchio, D.; Barsdorf, A.; Mitsumoto, H.; Levin, B., Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol, 2009, 66(2), 235-244.
124. Hori, A.; Yoshida, M.; Shibata, T.; Ling, F., Reactive oxygen species regulate DNA copy number in isolated yeast mitochondria by triggering recombination-mediated replication. Nucleic Acids Res, 2009, 37(3), 749-761.
125. Strobel, N.A.; Peake, J.M.; Matsumoto, A.; Marsh, S.A.; Coombes, J.S.; Wadley, G.D., Antioxidant Supplementation Reduces Skeletal Muscle Mitochondrial Biogenesis. Med Sci Sports Exerc, 2010.
126. Bjelakovic, G.; Nikolova, D.; Gluud, L.L.; Simonetti, R.G.; Gluud, C., Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA, 2007, 297(8), 842-857. (Pubitemid 46333949)
127. Yang, L.; Calingasan, N.Y.; Wille, E.J.; Cormier, K.; Smith, K.; Ferrante, R.J.; Beal, M.F., Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem, 2009, 109(5), 1427-1439.
128. Wen, Y.; Li, W.; Poteet, E.C.; Xie, L.; Tan, C.; Yan, L.J.; Ju, X.; Liu, R.; Qian, H.; Marvin, M.A.; Goldberg, M.S.; She, H.; Mao, Z.; Simpkins, J.W.; Yang, S.H., Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem, 2011, 286(18), 16504-15.